McKenzie Prillaman

When Larry Einhorn was a young physician in the early 1970s, actinomycin-D was the standard drug used to treat testicular cancer. It was—and still is—the most common carcinoma in young men ages 15-35. 

Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy. 

A mathematical puzzle fascinated Susan Ellenberg as a child.

A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.

Hispanic and Latino people comprise nearly 20% of the U.S. population, but less than 6% of physicians nationwide identify as Hispanic.

On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 

Mace Rothenberg has stayed busy since stepping down as Pfizer’s chief medical officer in 2021 by pivoting to an ambitious endeavor in science communication: the Museum of Medicine and Biomedical Discovery. 

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

Something odd turned up in one of Lawrence Phillips’s routine health screenings in 2008.

What will happen to biomedical research and health care in the aftermath of the 2024 election? The differences in outcomes couldn’t be more stark. 

Source: Livestream of White House Africa Cancer Care ForumThe White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries. 

Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.

Kate Choi grew up hearing conversations about skin cancer. Her grandparents had it, as did her cousins. 

Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research. 

The NCI Board of Scientific Advisors approved five new concepts and 17 reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board June 11-12. 

Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.

NCI Director Kimryn Rathmell joined the NIH director and four other institute directors in a May 23 Senate subcommittee hearing to craft the Labor-HHS spending bill for fiscal year 2025.

Unquestionably, a child’s cancer diagnosis weighs heavily on the parents’ minds. But now, an analysis of nearly 30,000 U.S. families has quantified how often parents of children with cancer use mental health services. 

The Biden administration has—for the second time—delayed the decision on a proposed FDA rule that would ban menthol cigarettes and all flavors in cigars. 

Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study published in the April issue of Clinical Lymphoma, Myeloma, and Leukemia.

Something felt wrong during one of Morhaf Al Achkar’s regular runs on the treadmill in late 2016. He started gasping for breath.